Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers.

PURPOSE

Fibroblast activation protein (FAP) has emerged as one of the most promising theranostic targets. FT-FAPI, a potential FAP-targeted probe with enhanced tumor-targeting ability using an organotrifluoroborate linker, was verified for the biological effect in cell and animal experiments in previous work. However, the differences in pharmacokinetic profiles, biodistribution and dosimetry of FT-FAPI under multiple nuclides labeling in animals and humans is unclear. In this study, we sought to explore the discrepancies in the performance of FT-FAPI after labeling with different radioisotopes and to compare Ga-FT-FAPI with Ga-FAPI-04 in healthy volunteers.

METHODS

Preparation and quality control of F-/Ga-/Lu-FT-FAPI injections were conducted. Biodistribution studies were performed in mice and pharmacokinetic analysis were performed using blood samples. F-FT-FAPI and Ga-FT-FAPI were initially tested in normal volunteers, respectively. Further, Ga-FT-FAPI was scanned at multiple time points for 1 h dynamic, 2 h and 3 h static imaging, and compared with Ga-FAPI-04 to clarify the distribution patterns and excretion parameters. Radiation dosimetry was estimated based on the uptake of the probes in organs of mice or humans, respectively.

RESULTS

F-/Ga-/Lu-FT-FAPI showed high safety and tolerability in mice or humans. The pharmacokinetic characteristics of FT-FAPI in mice and humans best fit a two-compartment model. In mice, the results of biodistribution showed that the clearance half-life (T) of FT-FAPI varied with different labeled radionuclides, with Ga-FT-FAPI having the shortest T of 26.1 min. In HT-1080-FAP tumor-bearing mice, Lu-FT-FAPI showed higher tumor uptake and longer retention time than Lu-FAPI-04, which implies a higher radiation dose in the tumor. In healthy volunteers, both F-FAPI-04 and Ga-FT-FAPI were metabolized by the kidneys and excreted through the urinary system. The uptake of Ga-FT-FAPI in most normal tissues was similar to that of Ga-FAPI-04, being higher only in the sublingual gland, thyroid gland and pancreas. Ga-FT-FAPI had similar T (75.0 min vs. 77.2 min) and a slightly higher effective dose (ED) (12.4 ± 1.51 µSv·MBq vs. 9.99 ± 1.85 µSv·MBq) compared to Ga-FAPI-04. Compared to Ga-FT-FAPI, F-FT-FAPI has slightly higher liver and bone uptake, especially in the delayed time points.

CONCLUSION

The pharmacokinetics of FT-FPAI varies depending on the labeled nuclide. Compared to Lu-FAPI-04, Lu-FT-FAPI showed higher tumor uptake and longer retention time. In healthy volunteers, Ga-FT-FAPI had lower renal uptake and higher sublingual gland, thyroid gland and pancreas uptake at 1 h p.i. than that of Ga-FAPI-04, with no significant differences in other organs. Further optimization will be conducted for the radiolabeling process of F-FT-FAPI to evaluate its diagnostic efficacy.